Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma
Phase 1/2 Recruiting
36 enrolled
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
Phase 1/2 Recruiting
442 enrolled
A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors
Phase 1/2 Recruiting
280 enrolled
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Phase 1/2 Recruiting
616 enrolled
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Phase 1/2 Recruiting
252 enrolled
ALTAIR
Phase 1/2 Recruiting
152 enrolled
KRAScendo 170
Phase 1/2 Recruiting
320 enrolled
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Phase 1/2 Recruiting
370 enrolled
Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer
Phase 1/2 Recruiting
29 enrolled
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
Phase 1/2 Recruiting
40 enrolled
MK-9999-02A
Phase 1/2 Recruiting
220 enrolled
Acclaim-1
Phase 1/2 Recruiting
158 enrolled
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Phase 1/2 Recruiting
50 enrolled
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
660 enrolled
SOLARA
Phase 1/2 Recruiting
41 enrolled
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
Phase 1/2 Recruiting
248 enrolled
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
320 enrolled
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
Phase 1/2 Recruiting
54 enrolled
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
Phase 1/2 Recruiting
202 enrolled
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
444 enrolled
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Phase 1/2 Recruiting
490 enrolled
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Phase 1/2 Recruiting
540 enrolled
Establishing Best Treatment Strategy for T4 Esophageal Cancer
Phase 1/2 Recruiting
22 enrolled
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Phase 1/2 Recruiting
100 enrolled
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Phase 1/2 Recruiting
148 enrolled
Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma
Phase 1/2 Recruiting
30 enrolled
RADIAN
Phase 1/2 Recruiting
34 enrolled
Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC
Phase 1/2 Recruiting
27 enrolled
Chemoradiotherapy in Unresectable Esophageal Cancer
Phase 1/2 Recruiting
105 enrolled
Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.
Phase 1/2 Recruiting
93 enrolled
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Phase 1/2 Recruiting
45 enrolled
Study of ZG005 in Combination With Paclitaxel+Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma
Phase 1/2 Recruiting
48 enrolled
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
Phase 1/2 Recruiting
50 enrolled